Philips and Merck partner to advance personalized fertility treatment
January 14 2021 - 4:00AM
January 14, 2021
Remote patient monitoring, cloud-based platform services and
mobile, AI-enabled ultrasound diagnostics to support improved
access to care and better outcomes in fertility treatment
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced a
multi-year partnership with Merck, a leading science and technology
company, to develop clinical-grade digital solutions for highly
personalized fertility treatment. Leveraging digital health
technologies, advanced informatics and mobile, AI-enabled
ultrasound diagnostics, these solutions will aim to better inform
patients and clinicians about the choice and timing of fertility
treatment to maximize the chances of conception.
“At Philips we are leading digital transformation in healthcare,
with a portfolio that includes solutions for both professionals and
consumers to support parents-to-be through pregnancy and the first
years of their baby’s life,” said Jeroen Tas, Chief Innovation
& Strategy Officer, Royal Philips. “The journey for aspiring
parents is sometimes a difficult one, and by collaborating with
Merck, a world leader in fertility treatment, we aim to develop
integrated digital solutions that improve the patient experience
and can ultimately have a positive impact on health outcomes. This
partnership builds on our expertise in maternal and fetal
monitoring, our Pregnancy+ and Baby+ consumer engagement apps, our
leading ultrasound solutions and our HealthSuite Cloud/AI
platform.”
“We believe that the future of IVF will be unlocked through
digital health technologies that empower professionals and patients
to be better connected,” said Michelangelo Canzoneri, Global Head
of Digital and Data, Healthcare at Merck. “With Philips, we have a
partner that shares our belief in the potential of digital health
to improve the patient experience, bringing a wealth of experience
in connected care to our offering. Together, this collaboration
will push our two companies to think beyond tomorrow and discover
new solutions that can empower people to realize their dreams of
parenthood,” added Jan Kirsten, Head of Global Business Franchise
for Fertility at Merck.
Digital health and virtual care technologies have proved
invaluable during the COVID-19 pandemic in keeping patients and
their care teams in virtual contact, accelerating digital
transformation in healthcare. Digital technologies including remote
patient monitoring, cloud-based services and AI are playing an ever
more important part in achieving better patient outcomes, better
patient and staff experiences, and low cost of care – the quadruple
aim of healthcare.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel.: +31 631 639
916E-mail: mark.groves@philips.com Twitter: mark_groves
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About Merck
Merck KGaA, a leading science and technology company, operates
across healthcare, life science and performance materials. Around
57,000 employees work to make a positive difference to millions of
people’s lives every day by creating more joyful and sustainable
ways to live. From advancing gene editing technologies and
discovering unique ways to treat the most challenging diseases to
enabling the intelligence of devices – the company is everywhere.
In 2019, Merck generated sales of €16.2 billion in 66
countries.
Scientific exploration and responsible entrepreneurship have
been key to Merck’s technological and scientific advances. This is
how Merck has thrived since its founding in 1668. The founding
family remains the majority owner of the publicly listed company.
Merck holds the global rights to the Merck name and brand. The only
exceptions are the United States and Canada, where the business
sectors of Merck operate as EMD Serono in healthcare,
MilliporeSigma in life science, and EMD Performance Materials.
- Obstetrics ultrasound imaging shown on the EPIQ Elite
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024